| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
|
Eggermont, Alexander M.M.
|
|
2019
|
119 |
C |
p. 1-10
|
artikel
|
| 2 |
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
|
Gogas, Helen J.
|
|
2019
|
119 |
C |
p. 97-106
|
artikel
|
| 3 |
Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma
|
Bastholt, Lars
|
|
2019
|
119 |
C |
p. 122-131
|
artikel
|
| 4 |
A snapshot of current genetic testing practice in Lynch syndrome: The results of a representative survey of 33 Latin American existing centres/registries
|
Della Valle, Adriana
|
|
2019
|
119 |
C |
p. 112-121
|
artikel
|
| 5 |
Breastfeeding during R-CHOP chemotherapy: please abstain!
|
Codacci-Pisanelli, Giovanni
|
|
2019
|
119 |
C |
p. 107-111
|
artikel
|
| 6 |
Cancer invasion regulates vascular complexity in a three-dimensional biomimetic model
|
Pape, Judith
|
|
2019
|
119 |
C |
p. 179-193
|
artikel
|
| 7 |
Challenging the recalcitrant disease—developing molecularly driven treatments for small cell lung cancer
|
Mak, Daisy W.S.
|
|
2019
|
119 |
C |
p. 132-150
|
artikel
|
| 8 |
Clinical and genetic analysis of melanomas arising in acral sites
|
Zaremba, Anne
|
|
2019
|
119 |
C |
p. 66-76
|
artikel
|
| 9 |
Corrigendum to ‘A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours’ [Eur J Cancer 104 (November 2018) 1–8]
|
Gazzah, Anas
|
|
2019
|
119 |
C |
p. 198
|
artikel
|
| 10 |
Corrigendum to “Parasites and immunotherapy: Immunostimulatory effect of Leishmania spp. in cancer treatment” [Eur J Cancer 110 (1) (March 2019) S33]
|
Caner, A.
|
|
2019
|
119 |
C |
p. 199
|
artikel
|
| 11 |
Deep neural networks are superior to dermatologists in melanoma image classification
|
Brinker, Titus J.
|
|
2019
|
119 |
C |
p. 11-17
|
artikel
|
| 12 |
Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ [Eur J Cancer 108 (February 2019) 33–40]
|
Auvray, Marie
|
|
2019
|
119 |
C |
p. 200-201
|
artikel
|
| 13 |
Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study
|
Gallois, Claire
|
|
2019
|
119 |
C |
p. 35-43
|
artikel
|
| 14 |
Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma
|
Kanaki, Theodora
|
|
2019
|
119 |
C |
p. 18-29
|
artikel
|
| 15 |
Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial
|
Yang, Qi
|
|
2019
|
119 |
C |
p. 87-96
|
artikel
|
| 16 |
Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy
|
Mekki, Ahmed
|
|
2019
|
119 |
C |
p. 44-56
|
artikel
|
| 17 |
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors
|
Chang, Lih-Chyun
|
|
2019
|
119 |
C |
p. 77-86
|
artikel
|
| 18 |
Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data
|
Sondermann, Wiebke
|
|
2019
|
119 |
C |
p. 30-34
|
artikel
|
| 19 |
Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study
|
Le Cesne, A.
|
|
2019
|
119 |
C |
p. 151-157
|
artikel
|
| 20 |
Reply to ‘The use of buparlisib as a radiosensitiser: What about toxicity?’
|
McGowan, Daniel R.
|
|
2019
|
119 |
C |
p. 196-197
|
artikel
|
| 21 |
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)
|
Nathan, Paul
|
|
2019
|
119 |
C |
p. 168-178
|
artikel
|
| 22 |
SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer
|
Munemoto, Y.
|
|
2019
|
119 |
C |
p. 158-167
|
artikel
|
| 23 |
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks
|
Maron, Roman C.
|
|
2019
|
119 |
C |
p. 57-65
|
artikel
|
| 24 |
The use of buparlisib as a radiosentisiser: What about toxicity?
|
van Dam, Peter A.
|
|
2019
|
119 |
C |
p. 194-195
|
artikel
|
Tijdschrift beschrijving